solid tumours

GlobalData, a data and analytics company, has reported that further development of chimeric antigen receptor (CAR)-T cell therapies in solid tumours will require collaboration with industry. Read more


Catalent Pharma Solutions has signed a multi-year agreement with Grid Therapeutics for the development and manufacture of a lead therapeutic candidate for the treatment of solid tumours. Read more